Executive Interviews
The New ‘Blue’ Gold: Canopy Blue’s $10bn Bet on the Humble Seaweed
What if the answer to soil degradation was underwater? Canopy Blue CEO Josh Masel discusses the “commercial moat” of seaweed aquaculture and the massive offtake potential in animal feed and pharmaceuticals.
From Lick Blocks to Ledger: Why This ‘Boring’ Tech is the New AgTech Gold
In the Australian Outback, 92% of livestock live in extensive grazing systems where consistent nutrition is a logistical nightmare. Mark Peart is changing that by turning the “last mile” of farming into a digital ledger. Learn how DIT AgTech’s uDOSE™ platform is bridging the gap between generational legacy and the global carbon market.
Blockchain, Biometrics, and Bullion: How Kavach is Digitising the Family Safe
As Australian banks phase out physical safety lockers, Kavach is stepping in with a high-tech network of suburban vaults. Combining AI threat detection with private blockchain verification, founder Dinesh Dindukurthi is digitising the family safe for a new generation of wealth.
Australia’s 60,000 Business Succession Crisis: Why Good Companies Will Close Their Doors
The Australian Business Growth Fund identified approximately 162,000 privately held businesses in Australia with revenue between AUD$2 million and AUD$100 million. More than two-thirds are owned by people of retirement age. When surveyed, another two-thirds do not have a succession plan in place. The mathematics are stark. 60,000 businesses owned by someone of retirement age […]
The ‘Banknote’ Blueprint: Halocell’s Plan to Print the Next Solar Revolution
Beyond rooftops—Halocell Energy’s “banknote” printing creates highly efficient, flexible, lightweight, recyclable and cost-effective solar cells for shaded areas and from dawn to dusk, detailing the three-horizon plan.
The Iron Chaperone: Alterity’s High-Stakes Sprint on Brain Iron Redistribution
Multiple System Atrophy (MSA) is a devastating neurological disease with no known cure. Alterity Therapeutics is breaking the “black box” of MSA with ATH434, a first-in-class drug that targets toxic iron accumulation. After successful Phase 2 results, the company is now scaling for a pivotal Phase 3 trial, positioning itself as a frontrunner in a multi-billion dollar orphan drug market.
The ‘Unused Billion’: How Points4Purpose is Disrupting the Flatlining Loyalty Market
The loyalty industry is plagued by “sameness,” leaving billions in value dormant. Ivan Schwartz’s Points4Purpose is disrupting this flatlining market by turning rewards into a liquid currency for rent, bills, and over 1.8 million charities.
1,000km, sustainable, efficient , no onboard pilot: How ‘Gap Drone ’ is rewriting the rules of remote logistics
Can autonomous drones solve Australia’s “tyranny of distance”? GAP Drone CEO Liesl Haris thinks so. With the launch of ATLAS—an autonomous transport logistics aircraft system—the company is bypassing traditional infrastructure to deliver 50kg payloads over 1,000km. Dubbed the “Uber of airfreight,” GAP Drone is tackling the “too hard basket” of remote logistics, partnering with Australia Post to provide First Nations communities and regional hubs with reliable, low-cost access to medicine, food, and economic opportunity. By operating within current regulatory frameworks and utilising a “no-runway” launch model, GAP Drone is transforming air freight from an expensive luxury into a scalable utility.
Precision Care, Zero Clicks: Why the Future of the NDIS is Voice-First
Carelogix is solving the healthcare burnout crisis by replacing manual typing with a sophisticated AI “care co-pilot.” By reclaiming nearly half of a caregiver’s day, the platform offers a significant value inflection point for providers and investors in the trillion-dollar care economy.
Backed By Leading Investment Groups and Family Offices
